Dr. Sarah Bolander, DMSc, PA-C
Pemphigoid gestationis (PG), a vesiculobullous autoimmune disorder, occurs in 1 in 20,000 pregnancies worldwide with potentially significant morbidity to the pregnant person. Though the clinical presentation may vary, PG is most commonly associated with a severe pruritic rash that may progress to tense bullae with potential premature birth and small-for-gestational-age births. As PG is associated with significant morbidity and fetal risk, the clinician must recognize symptoms early for appropriate treatment and referral if necessary. Treatment should focus on the reduction of maternal pruritis and the prevention of advancement of symptoms. Potential treatment options may include topical or systemic corticosteroids, antihistamines, or Intravenous Immunoglobulin (IVIG). Because PG is a rare autoimmune blistering skin disease associated exclusively with pregnancy that may carry extensive risk to pregnant persons and babies, early identification and referral are essential for all persons presenting with this disorder.
Merson J. Dermatology Grand Rounds: Recognition and Management of Pemphigoid Gestationis. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.